Latest & greatest articles for hydroxychloroquine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hydroxychloroquine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on hydroxychloroquine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for hydroxychloroquine

1. COVID-19 Clinical Trials Report Card: Chloroquine and Hydroxychloroquine

COVID-19 Clinical Trials Report Card: Chloroquine and Hydroxychloroquine COVID-19 Clinical Trials Report Card: Chloroquine and Hydroxychloroquine - CEBM CEBM The Centre for Evidence-Based Medicine develops, promotes and disseminates better evidence for healthcare. Navigate this website COVID-19 Clinical Trials Report Card: Chloroquine and Hydroxychloroquine May 11, 2020 Nicholas J. DeVito, Michael Liu, Jeffrey K Aronson On behalf of the Oxford COVID-19 Evidence Service Team Centre for Evidence (...) -Based Medicine, Nuffield Department of Primary Care Health Sciences University of Oxford Correspondence to Chloroquine and hydroxychloroquine (CQ/HCQ) are antimalarial medications and are also used in the treatment of lupus erythematosus and rheumatoid arthritis. Both have been prominently touted as prospective candidates for the treatment and/or prevention of infection by SARS-Cov-2. This has led to an explosion of research into these treatments. Here we assess the trial designs specified

2020 Oxford COVID-19 Evidence Service

2. Covid-19: New data on the cardiac adverse effects of the combination of hydroxychloroquine (Plaquenil) with azithromycin (Zithromax or other brands) Full Text available with Trip Pro

Covid-19: New data on the cardiac adverse effects of the combination of hydroxychloroquine (Plaquenil) with azithromycin (Zithromax or other brands) Prescrire IN ENGLISH - Spotlight ''New data on the cardiac adverse effects of the combination of hydroxychloroquine (Plaquenil°) with azithromycin (Zithromax° or other brands)'', 16 April 2020 {1} {1} {1} | | > > > New data on the cardiac adverse effects of the combination of hydroxychloroquine (Plaquenil°) with azithromycin (Zithromax° or other (...) brands) Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight New data on the cardiac adverse effects of the combination of hydroxychloroquine (Plaquenil°) with azithromycin (Zithromax° or other brands) NEWS UPDATE As of mid-April 2020, more and more clinical data are confirming that the combination of hydroxychloroquine (Plaquenil°) with azithromycin

2020 Prescrire

3. Covid-19 and hydroxychloroquine (Plaquenil): new data show no evidence of efficacy Full Text available with Trip Pro

Covid-19 and hydroxychloroquine (Plaquenil): new data show no evidence of efficacy Prescrire IN ENGLISH - Spotlight ''Covid-19 and hydroxychloroquine (Plaquenil°): new data show no evidence of efficacy'', 16 April 2020 {1} {1} {1} | | > > > Covid-19 and hydroxychloroquine (Plaquenil°): new data show no evidence of efficacy Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |    (...) |   |  Spotlight Covid-19 and hydroxychloroquine (Plaquenil°): new data show no evidence of efficacy NEWS UPDATE The results of a new randomised comparative but non-blinded trial of high-dose hydroxychloroquine (Plaquenil°) versus standard care in 150 patients hospitalised for covid-19 have been published. The only notable difference between the groups was the high incidence of adverse effects in the group treated with hydroxychloroquine. The results of other studies (non-randomised

2020 Prescrire

4. Ventricular Arrhythmia Risk Due to Hydroxychloroquine-Azithromycin Treatment For COVID-19

Ventricular Arrhythmia Risk Due to Hydroxychloroquine-Azithromycin Treatment For COVID-19 Ventricular Arrhythmia Risk Due to Hydroxychloroquine-Azithromycin Treatment For COVID-19 - American College of Cardiology ') Search All Types Search or Menu and use of hydroxychloroquine and chloroquine in clinical practice are outlined below. Hydroxychloroquine or chloroquine therapy should occur in the context of a clinical trial or registry, until sufficient evidence is available for use in clinical (...) practice. Hydroxychloroquine or chloroquine use outside of a clinical trial should occur at the direction of an infectious disease or COVID-19 expert, with cardiology input regarding QT monitoring. with detailed and general arrhythmia monitoring considerations are also available. The intensity of QT and arrhythmia monitoring should be considered in the context of potential drug benefit, drug safety, resource availability and quarantine considerations. IRB-approved protocols should guide use

2020 American College of Cardiology

5. Hydroxychloroquine with or without azithromycin for COVID-19

Hydroxychloroquine with or without azithromycin for COVID-19 Tools for Practice is proudly sponsored by the Alberta College of Family Physicians (ACFP). ACFP is a provincial, professional voluntary organization, representing more than 4,800 family physicians, family medicine residents, and medical students in Alberta. Established over sixty years ago, the ACFP strives for excellence in family practice through advocacy, continuing medical education and primary care research. www.acfp.ca March 30 (...) , 2020 COVID-19 Rapid Reviews Along with regular Tools for Practice, the PEER team will be writing rapid reviews to address COVID-19 topics relevant for primary care. The evidence is changing rapidly and it is possible that as you read this, new evidence will already be available. We will try our best to stay in front and keep you up-to- date during these challenging times. Hydrochloroquine with or without azithromycin for COVID-19 Clinical Question: Is hydroxychloroquine (with or without

2020 Tools for Practice

6. Covid-19 and hydroxychloroquine: caution

Covid-19 and hydroxychloroquine: caution Prescrire IN ENGLISH - Spotlight ''Covid-19 and hydroxychloroquine: caution '', 30 March 2020 {1} {1} {1} | | > > > Covid-19 and hydroxychloroquine: caution Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Covid-19 and hydroxychloroquine: caution NEWS UPDATE Hydroxychloroquine was not shown to be effective (...) in a randomised trial in 30 patients with covid-19, the results of which were published in China in early March 2020. The hypothesis that this drug sometimes worsens covid-19 has not been ruled out. Short-course treatment with hydroxychloroquine carries a risk of various adverse effects, some of which can be fatal, especially in the event of an overdose. As of 23 March 2020, we were unable to identify any published results of randomised trials of hydroxychloroquine in patients with SARS-CoV-2 infection, i.e

2020 Prescrire

7. Covid-19 and hydroxychloroquine: uncertainties and unanswered questions

Covid-19 and hydroxychloroquine: uncertainties and unanswered questions Prescrire IN ENGLISH - Spotlight ''Covid-19 and hydroxychloroquine: uncertainties and unanswered questions '', 02 April 2020 {1} {1} {1} | | > > > Covid-19 and hydroxychloroquine: uncertainties and unanswered questions Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Covid-19 (...) and hydroxychloroquine: uncertainties and unanswered questions NEWS UPDATE Results of a comparative trial of hydroxychloroquine (Plaquenil°) in 62 patients were published at the end of March 2020. The remaining uncertainty in the wake of these results means that the comparative trials currently underway must be continued, and great care should still be taken in the use of hydroxychloroquine, given its cardiac and other harms. Results of a Chinese comparative trial of hydroxychloroquine (Plaquenil°) were published

2020 Prescrire

8. Guiding Principles from the American College of Rheumatology for Scarce Resource Allocation During the COVID-19 Pandemic: The Case of Hydroxychloroquine

Guiding Principles from the American College of Rheumatology for Scarce Resource Allocation During the COVID-19 Pandemic: The Case of Hydroxychloroquine Guiding Principles from the American College of Rheumatology for Scarce Resource Allocation During the COVID-19 Pandemic: The Case of Hydroxychloroquine Background Ethical principles must be balanced when making decisions about scarce resource allocation. In extreme circumstances, like the COVID-19 pandemic caused by the SARS-CoV-2 virus (...) , the focus of medical care “shifts from the needs of the individual (ethical principle of autonomy) to the needs of the community as a whole (ethical principle of distributive justice)” (1) with the goal of achieving the greatest good for the greatest number of people. Hydroxychloroquine (HCQ) is an essential medicine for patients with systemic lupus erythematosus (SLE). It is also a mainstay of therapy for many patients with rheumatoid arthritis. In the case of SLE, including pregnant women with SLE

2020 American College of Rheumatology

9. Chloroquine and hydroxychloroquine: Current evidence for their effectiveness in treating COVID-19

Chloroquine and hydroxychloroquine: Current evidence for their effectiveness in treating COVID-19 Chloroquine and hydroxychloroquine: Current evidence for their effectiveness in treating COVID-19 - CEBM CEBM The Centre for Evidence-Based Medicine develops, promotes and disseminates better evidence for healthcare. Navigate this website Chloroquine and hydroxychloroquine: Current evidence for their effectiveness in treating COVID-19 March 25, 2020 KERSTIN FRIE and KOME GBINIGIE Oxford COVID-19 (...) Evidence Service Team Centre for Evidence-Based Medicine, Nuffield Department of Primary Care Health Sciences University of Oxford Correspondence to oghenekome.gbinigie@phc.ox.ac.uk 26/03/2020 VERDICT Several in vitro studies report antiviral activity of chloroquine and hydroxychloroquine against SARS-CoV-2. In vivo data, although promising, is currently limited to one study with considerable limitations. On the basis of the weak evidence available to date, treatment guidelines have already

2020 Oxford COVID-19 Evidence Service

10. Statistical review of Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

Statistical review of Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial application/octet-stream

2020 Covid-19 Ad hoc papers

11. Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries

Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries Redirecting

2020 Covid-19 Ad hoc papers

12. Hydroxychloroquine for COVID-19: What do the clinical trials tell us?

Hydroxychloroquine for COVID-19: What do the clinical trials tell us? Hydroxychloroquine for COVID-19: What do the clinical trials tell us? - CEBM CEBM The Centre for Evidence-Based Medicine develops, promotes and disseminates better evidence for healthcare. Navigate this website Hydroxychloroquine for COVID-19: What do the clinical trials tell us? April 14, 2020 Robin E Ferner*, Jeffrey K Aronson On behalf of the Oxford COVID-19 Evidence Service Team Centre for Evidence-Based Medicine (...) , Nuffield Department of Primary Care Health Sciences University of Oxford *University of Birmingham Correspondence to VERDICT Current data do not support the use of hydroxychloroquine for prophylaxis or treatment of COVID-19. There are no published trials of prophylaxis. Two trials of hydroxychloroquine treatment that are in the public domain, one non-peer reviewed, are premature analyses of trials whose conduct in both cases diverged from the published skeleton protocols registered on clinical trial

2020 Oxford COVID-19 Evidence Service

13. Hydroxychloroquine or Chloroquine for treating COVID-19 – a PROTOCOL for a systematic review of IPD

Hydroxychloroquine or Chloroquine for treating COVID-19 – a PROTOCOL for a systematic review of IPD Hydroxychloroquine or Chloroquine for treating COVID-19 – a PROTOCOL for a systematic review of IPD - CEBM CEBM The Centre for Evidence-Based Medicine develops, promotes and disseminates better evidence for healthcare. Navigate this website Hydroxychloroquine or Chloroquine for treating COVID-19 – a PROTOCOL for a systematic review of IPD April 14, 2020 Hydroxychloroquine or Chloroquine (...) pharmacological interventions such as antimalarial drugs, antiviral drugs, biologics, and interferon. The number of trial registrations for hydroxychloroquine/cholorquine as a COVID-19 therapeutic rises each day and on April 5 th 2020 we found three published trials and 100 ongoing studies. A first published report from Gautret et al. (1) suggested a positive effect of hydroxychloroquine (plus azithromycin, an antibiotic, in some cases) on the disappearance of COVID-19, attracting intense media coverage

2020 Oxford COVID-19 Evidence Service

14. COVID-19: Prophylactic Use of Hydroxychloroquine (HCQ)

COVID-19: Prophylactic Use of Hydroxychloroquine (HCQ) COVID-19: PROPHYLACTIC USE OF HYDROXYCHLOROQUINE (HCQ) A Rapid Guidance Summary from the Penn Medicine Center for Evidence-based Practice Last updated April 21, 2020 10:00 pm All links rechecked April 20 unless otherwise noted. Key questions answered in this summary • Is hydroxychloroquine effective for prevention of clinical disease in patients who have been exposed to the 2019-nCoV coronavirus? Use of hydroxychloroquine for treatment (...) of confirmed COVID-19 disease is outside the scope of this report. Summary of major recommendations • There are no clinical guidelines that support use of hydroxychloroquine or chloroquine for prevention of COVID-19 disease outside of approved clinical trials. • There are no hospitals using hydroxychloroquine or chloroquine for prevention of COVID-19 disease outside of approved clinical trials. Guidelines on prophylactic use of hydroxychloroquine Source Recommendations Public health agencies CDC April 13

2020 Centre for Evidence-Based Practice, Penn Medicine

15. COVID-19: Treatment with Hydroxychloroquine (HCQ)

COVID-19: Treatment with Hydroxychloroquine (HCQ) COVID-19: TREATMENT WITH HYDROXYCHLOROQUINE (HCQ) A Rapid Guidance Summary from the Penn Medicine Center for Evidence-based Practice Last updated April 22, 2020 12:00 pm All links rechecked April 21 unless otherwise noted. Key questions answered in this summary • Is hydroxychloroquine effective for treatment of COVID-19 disease? Use of hydroxychloroquine for prevention of COVID-19 disease is outside the scope of this report. Summary of major (...) recommendations • Use of hydroxychloroquine and chloroquine for treatment of COVID-19 disease is considered an off-label indication. Clinical trials are in progress. • Use of hydroxychloroquine and chloroquine outside of clinical trials should be limited to hospitalized patients. • Current clinical evidence on hydroxychloroquine is from small, low-quality studies, with conflicting results (GRADE strength of evidence evaluation: very low). • Most but not all hospitals whose guidance we reviewed are suggesting

2020 Centre for Evidence-Based Practice, Penn Medicine

16. [Hydroxychloroquine to obtain pregnancy without adverse obstetrical events in primary antiphospholipid syndrome: French phase II multicenter randomized trial, HYDROSAPL]. (Abstract)

[Hydroxychloroquine to obtain pregnancy without adverse obstetrical events in primary antiphospholipid syndrome: French phase II multicenter randomized trial, HYDROSAPL]. Antiphospholipid syndrome is defined by the presence of thrombosis and/or obstetrical adverse events (≥3 recurrent early miscarriage or fetal death or a prematurity<34 weeks of gestation) associated with persistent antiphospholipid antibodies. The pregnancy outcome has been improved by the conventional treatment (aspirin 100mg (...) anticoagulant and APL triple positivity are considered as factors associated with unfavorable obstetrical outcome. Hydroxychloroquine (HCQ) has anti-inflammatory and anti-thrombotic properties. Studies in vitro have shown that HCQ is able to restore the placental expression of Annexin V, which has an anticoagulant effect and to prevent the placental injury induced by APL. HCQ used for lupus erythematosus decrease the thrombotic risk and its value for thrombotic APS has been raised in an open labelled French

2018 Gynecologie, obstetrique, fertilite & senologie Controlled trial quality: uncertain

17. Efficacy of Hydroxychloroquine in Hand Osteoarthritis: A Randomized, Double-Blind, Placebo-Controlled Trial Full Text available with Trip Pro

Efficacy of Hydroxychloroquine in Hand Osteoarthritis: A Randomized, Double-Blind, Placebo-Controlled Trial To determine the symptom-modifying effect of hydroxychloroquine (HCQ) in hand osteoarthritis (OA).In this randomized, double-blind, multicenter trial, patients with symptomatic hand OA received either HCQ 400 mg once a day or placebo during 24 weeks. The primary outcome was change of pain measured on a 100-mm visual analog scale (VAS) at 24 weeks. Secondary outcomes included decrease

2018 EvidenceUpdates

18. Hydroxychloroquine

Hydroxychloroquine Top results for hydroxychloroquine - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2 (...) ) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for hydroxychloroquine The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms

2018 Trip Latest and Greatest

19. A case of exogenous ochronosis associated with hydroxychloroquine Full Text available with Trip Pro

A case of exogenous ochronosis associated with hydroxychloroquine Exogenous ochronosis is characterized by hyperpigmented skin lesions that arise in association with local suppression of homogentisic acid oxidase enzyme. Although it generally develops in association with topical application of chemical agents, it can occasionally develop in association with antimalarial drugs. Here we present the case of a patient with rheumatoid arthritis who developed hyperpigmentation on the face and neck (...) regions during hydroxychloroquine treatment. Hydroxychloroquine is being widely used in rheumatology practice, and cutaneous hyperpigmentation may develop as an adverse effect. In the present case, we emphasize the potential underlying mechanisms through which it may cause cutaneous hyperpigmentation and determine the clinical and histopathological findings of exogenous ochronosis.

2018 European journal of rheumatology

20. Hydroxychloroquine Effectiveness in Reducing Symptoms of Hand Osteoarthritis: A Randomized Trial. Full Text available with Trip Pro

Hydroxychloroquine Effectiveness in Reducing Symptoms of Hand Osteoarthritis: A Randomized Trial. Synovitis is believed to play a role in producing symptoms in persons with hand osteoarthritis, but data on slow-acting anti-inflammatory treatments are sparse.To determine the effectiveness of hydroxychloroquine versus placebo as an analgesic treatment of hand osteoarthritis.Randomized, double-blind, placebo-controlled clinical trial with 12-month follow-up. (ISRCTN registry number: ISRCTN91859104 (...) numerical rating scale [NRS]) at 6 months. Secondary end points included self-reported pain and function, grip strength, quality of life, radiographic structural change, and adverse events. Baseline ultrasonography was done.At 6 months, mean hand pain was 5.49 points in the placebo group and 5.66 points in the hydroxychloroquine group, with a treatment difference of -0.16 point (95% CI, -0.73 to 0.40 point) (P = 0.57). Results were robust to adjustments for adherence, missing data, and use of rescue

2018 Annals of Internal Medicine Controlled trial quality: predicted high